Articles On Noxopharm (ASX:NOX)
| Title | Source | Codes | Date |
|---|---|---|---|
|
Noxopharm Eyes The Development Of A Well-Tolerated ‘STING agonist’ Drug
Noxopharm Limited (ASX: NOX) has released July 2019 edition of its Newsletter called ‘Versatility’. The clinical-stage drug development company, Noxopharm reports on the progress of its lead anti-cancer drug candidate Veyonda® achieved over... |
Kalkine Media | NOX | 6 years ago |
|
Noxopharm’s clinical programs aiming to unveil a potential blockbuster drug in the cancer treatment spectrum
Clinical stage drug development company, Noxopharm Limited (ASX: NOX) aims to bring hope to cancer patients who have reached the end of their treatment journey and have no standard treatment options remaining, except palliative therapy for... |
Kalkine Media | NOX | 6 years ago |
|
Potential ground-breaking outcomes for Veyonda® at SNMMI 2019 Conference
In the world of cancer, one billion-dollar molecule that has been making a big noise for its potential to extend life in men with the late-stage prostate cancer, concerns an experimental radioactive drug called Lutetium-177 (177Lu) labelled... |
Kalkine Media | NOX | 6 years ago |
|
Another tick for Noxopharm’s Veyonda® at SNMMI 2019 Annual Meeting
The big noise internationally in the treatment of prostate cancer is an experimental drug called 177Lu-PSMA-617. It is what is called a radiopharmaceutical, meaning that it is a radioactive drug that is injected intravenously. It is a way o... |
Kalkine Media | NOX | 6 years ago |
|
Noxopharm: Developing Veyonda® As A Universal Treatment Of Metastatic Cancer Disease
Clinical-stage drug development company, Noxopharm Limited (ASX: NOX) has released its updated corporate presentation for June 2019. The company, with offices in Sydney, New York and Hong Kong, is developing its leading drug candidate, Veyo... |
Kalkine Media | NOX | 6 years ago |
|
Noxopharm’s Nyrada receives cash rebate
07 Jun 2019 - Noxopharm (ASX:NOX) has seen its majority-owned US subsidiary company, Nyrada receive a cash rebate of over $486,000 under the Australian Government’s R&D Tax Incenti… |
FNN | NOX | 6 years ago |